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EXPERIMENTS in our laboratory have demonstrated that memory fixation of a shock- 
avoidance task in the goldfish can be blocked by puromycin or acetoxycycloheximide 
(AXM)$ when administered within 1 hr after training, but not at later times (AGRANOFF 
and KLINGER, 1964; DAVIS, BRIGHT and AGRANOFF, 1965; AGRANOFF, DAVIS and 
BRINK, 1965, 1966). The present studies report the effects of these compounds as well 
as actinomycin D on the incorporation of [3H]leucine into goldfish brain protein. 
MATERIALS A N D  M E T H O D S  
Experimental animals. Goldfish (Curassius aurutus) weighing 9-1 1 g were selected from weekly 
shipments of fish of 6-7 cm body length from Ozark Fisheries (Stoutland, Mo.). They were set out 
in individual 1.5 I. tanks 24 hr before the start of an experiment and were not fed subsequently. 
Reagents. Puromycin dihydrochloride (Nutritional Biochemicals Corp., Cleveland, Ohio) was 
dissolved at three concentrations, 5,  9 and 17 mg/ml in 0.15 M-NaC1, which is isotonic with goldfish 
serum (LEWNE and MUSALLAM, 1964). AXM was a gift of T. C. McBride, Chas. Pfizer and Co., 
Maywood, N. J., and was dissolved at a concentration of 10 pglml in 0.15 M-N~CI. Actinomycin D, 
generously supplied by Merck, Sharpe, and Dohme Co., West Point, Pa., was prepared at a con- 
centration of 0.2 mg/ml in 0.15 M-NaCI. ~-[4,5-~H]leucine hydrochloride in 0.01 N-HCI (5 mc/pmole, 
New England Nuclear Corp., Boston, Mass.) was neutralized with solid NaHCO, before use. 
Puromycin was injected intracranially (IC) as described previously (AGRANOFF and KLINGER, 1964). 
The labelled leucine was injected intraperitoneally (IP) with a 1.2 cm 20 gauge needle held at 45" to 
the lateral surface of the goldfish about 0.7 cm above the cloaca1 orsce. 
[SH]Leucine incorporation in bruin protein. At specified times following injections, fish were 
removed from their individual tanks. The spinal cord was severed with a scissors just posterior to the 
cranium, and the brain was exposed by removing the top of the skull. It was removed with a narrow 
spatula, blotted on paper towelling, and transferred to liquid nitrogen in a Dewar flask. The entire 
procedure took about 15 sec. Frozen brains (generally a pool of 10) were weighed and homogenized 
in 5 parts v/w of water at 4" in a Dual1 tissue grinder (Kontes Glass Co., Vineland, N.J.). 
Protein was isolated by a modification of the method of ROBERTS and MORELOS (1965). The 
aqueous brain homogenate was rapidly pipetted into an equal volume of 10% trichloroacetic acid 
with magnetic stirring. Following centrifugation of the finely divided protein suspension, the pre- 
cipitate was resuspended in 10 vol. (v/w, wet weight of brain) of 10% trichloroacetic acid and heated 
at 80" for 30 min with constant stirring. The precipitate obtained after centrifugation was washed 
twice with 5 vol. of 95 % ethanol, twice with 5 vol. of ether, dried and weighed A 10-15 mg portion 
of the dry protein was dissolved with heating at about 80" for 20 sec in 0 5  ml of 1 M-Hyamine 
hydroxide (Packard Instrument Co., Downers Grove, Ill.) in a counting vial and mixed with 10 ml of 
toluene-POPOP-PPO scintillation counting solution. A 0.1 ml portion of the supernatant fraction was 
diluted with 10 ml of xylene-dioxane-Cellosolve solution (BRUNO and CHRISTIAN, 1961). All samples 
were counted in a TriCarb liquid scintillation counter. Quenching corrections were made from a plot 
of quenching us. channel ratios. 
* This investigation was supported by grant No. GB 925 from the National Science Foundation. 
t Interdisciplinary training fellow under USPHS training grant No. 5T7-MH-7417. 
Abbreviations used: AXM, acetoxycycloheximide; IC, intracranial ; IP, intraperitoneal. 
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RESULTS 
Time course of rH]leucine uptake into brain protein. Preliminary experiments 
indicated that IC injections gave greater incorporation of [3H]leucine into protein 
than IP injections. However, there was considerable variability in the amount of 
radioactive leucine incorporated by the IC route. When rH]leucine was given IP, 
there was still considerable variation among individual fish. In subsequent experiments, 
ten fish brains were pooled for analysis (Table 1). When the ratio of radioactivity in 
protein to the radioactivity in the supernatant fraction was calculated, relatively small 
deviations from the means were observed. The ratio (disintegrations/min in protein/ 
disintegrations/min in supernatant fraction) x 100 obtained for groups of five or ten 
fish, was used in further experiments as an index of the inhibition of protein synthesis 
caused by different drugs. A ratio half that found in animals which received no puro- 
mycin represents 50 per cent inhibition. 
TABLE 1.-RADIOACTIVITY IN TRICHLOROACETIC ACID-SOLUBLE SUPERNATANT AND 






P* st (P/S) x 100 (€9 (mg) 
__  - -___ 
Individual fish 
Mean and S.D. 23.0 f 15.1 160.1 f 79.2 14.01 f 4.8 9.32 & 066 81.2 i 9.7 
N 59 59 59 40 40 
Groups of ten lish 
Mean and S.D. 22.5 f 6.3 150-3 f 39.9 15.1 2 1.3 - 86.1 f 3.9 
N 8 8 8 4 - .  
Goldfish were injected IP with 20 ,uc of [*H]leucine and killed 30 min later. Brains were analysed 
* P = disintegrations/min x 
t S = disintegrations/min x lo-* in trichloroacetic acid-soluble supernatant fraction/fish brain. 
individually or pooled in groups of 10. 
in protein/fish brain. 
To establish a time course for leucine incorporation into brain following IP 
injections, each goldfish in a group of five injected with 20 pc of [3H]leucine in a volume 
of 20 pl. A rapid incorporation of radioactivity into the supernatant fraction of brain 
was observed reaching a peak in about 1 hr and declining over the next day (Fig. l), 
while the radioactivity of protein was maximal in about 4 hr. During a 24 hr interval, 
approximately 20 per cent of the injected tritium appeared in the water of the fish 
tanks. Uptake into both fractions appeared linear for 30 min, and this interval was 
used for subsequent experiments. 
f i r o m p i n .  Groups of ten fish were injected IC with 10 pl of a solution contain- 
ing 50, 90, or 170pg of puromycin. At varying intervals thereafter, each animal 
received 20 pc of pH]leucine IP. The animals were removed from the tanks and killed 
30 min after the leucine injection, and the pooled brains analysed for radioactivity. 
The results (Table 2) show that with the three concentrations employed, puromycin 
rapidly depressed the incorporation of PHIleucine into brain protein. The rate of 
recovery from this inhibition, however, decreased as the dose of puromycin was 
increased. Animals that were given 50 or 90 pg of puromycin showed no significant 
inhibition by approximately 16 hr, while fish that received 170 pg required about 2 days 
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FIG. 1 .-Radioactivity in trichloroacetic acid-soluble U and insoluble 0 fractions of 
goldfish brain at various times following IP injection of 20 ,uc of [3H]leucine. Two 
groups of five fish were analysed for each time studied. Results are expressed as 
disintegrations/min/fish. 
TABLE 3.-INHIBlTION OF [3H]LEUCINE INCORPORATION INTO 
GOLDFISH BRAIN PROTEIN BY 0.1 /ALg ACETOXYCYCLOHEXIMIDE 
INJECTED I c  
Interval 
between IC 
AXM and IP 
[SH]leucine (hr) N* Pt St (P/S) x 100 
Control$ 
0.5 (2) 9.6 :! 2.0 198 & 14.0 
2 (2) 3.5 0.28 125.4 f 0.47 
8 (2) 4.4 f 0.45 163.7 & 19.9 
24 (2) 12.3 3.8 175.6 & 66.3 
72 (2) 10.7 f 3.8 119.6 C 8-45 
16.3 
4.9 + 0.7 
2.8 f 0.3 
2-7 f 0.1 
7.2 f 0.6 
8.9 rt 2.5 
* t See Table 2. 
AXM. Experiments similar to those described with puromycin were performed 
except that 0.1 pug of AXM was administered. The onset of inhibition of protein 
synthesis and the extent of inhibition (Table 3) were similar to these produced by 
170 pug of puromycin. However, the inhibition by AXM persisted much longer. 
Actinomycin D. In contrast to puromycin and AXM, an injection of 2 p g  of 
actinomycin D inhibited protein synthesis slowly (Table 4). The level of inhibition 
at 24 hr was similar to that seen with puromycin and AXM at 2 hr. Extensive inhibi- 
tion persisted for more than 3 days. During the 72 hr experimental period, none of the 
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fish died. Behavioural studies in this laboratory suggested, however, that this dose 
produced some degree of illness. When 1Opg of actinomycin D were injected IC, 
all of the fish died within 60 hr. 
Injuence of drug concentration on the inhibition of protein synthesis by AXM and 
purumycin. The relative effectiveness of puromycin and AXM in blocking brain 
protein synthesis was studied in fish that had received different doses of the two drugs. 
At 1 hr after receiving either drug IC, fish were given 20 pc of [3H]leucine IP and killed 
30min later. Inhibition of protein synthesis by the two drugs was expressed as a 
percentage of the ratio obtained for untreated control fish. The results in Fig. 2 show 
that AXM was much more effective in depressing protein synthesis than was puromy- 
cin. To attain 50 per cent inhibition, a 400- to 500-fold molar excess of puromycin to 
AXM was required. 
TABLE 4.-INHIBITION OF ['HILEUCINE INCORPORATION INTO 
GOLDFISH BRAIN PROTEIN BY 2 ,UCg OF ACTINOMYCIN D 





[*H]leucine (hr) N* . Pt st (P/S) x 100 
Control$ 16.3 
2 (2) 23.1 4.17 156.5 f 13.3 14.7 f 1.4 
8 (2) 14.2 f 6.93 136.0 f 45.6 10.2 i 1.7 
24 (2) 4.74 5 4.4 123.4 108.0 3-7 i- 0.3 
72 (2) 10.98 5 4.1 164.8 f 29.2 6-6 1.4 
* 7 $ See Table 2. 
DISCUSSION 
The present experiments confirm our preliminary findings (AGRANOFF, DAVIS and 
BRINK, 1965) that the extent and duration of inhibition of [3H]leucine incorporation 
into protein varies with the dose of puromycin administered. Expression of the results 
as a ratio of radioactivities rather than as specific activities produces more consistent 
estimates of the inhibitory effects of drugs. Variability in the injection site, the size 
of the brain, and of body pools, as well as the amount of leucine injected are minimized 
by the use of this ratio, which indicates how much of the labelled leucine entering the 
brain is incorporated into protein. When [3H]leucine is administered IP, 0.6 per cent 
of the injected radioactivity is found in the brain 1 hr later. The time course (Fig. 1) 
indicates a complex turnover involving at least two decay constants in the soluble 
fraction since a shoulder is seen. About 0.4 per cent of the injected dose appears in the 
trichloroacetic acid-precipitable fraction in about 4 hr. The level of radioactivity 
remains elevated after a slight initial decline. Sufficiently long times following puro- 
mycin to observe further loss of radioactivity were not examined. It is possible that 
the prolonged decay represents stable protein, or a slow equilibration with body pools 
of leucine outside of the brain. An apparent but not significant rise in the radioactivity 
in the trichloroacetic acid supernatant fraction 2 hr following a puromycin injection, 
resembling other reported increases (FLEXNER, FLEXNER, OBERTS and DE LA HABA, 
1964) is compensated for in our calculations of the degree of protein inhibition. 
FLEXNER, FLEXNER and STELLAR (1963) reported that intracerebral injections of puro- 
mycin can obliterate memory of maze training in mice when protein synthesis 
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pg of acetoxycyclohexirnide 
FIG. 2.-Inhibition of [SH]leucine incorporation into goldfish brain protein by 
puromycin and AXM. Drugs were injected at various concentrations 1 hr before VH]- 
leucine was injected IP. Animals were killed 30 min later. Percentage inhibition is 
calculated from the ratios of (P/S) x 100 of experimental groups compared to control 
groups. 
in bilateral temporal injection sites is reduced by 80 per cent for 8-10 hr. Behavioural 
experiments with subcutaneously injected puromycin or chloramphenicol did not 
produce a memory deficit (FLEXNER, FLEXNER, STELLAR, DE LA HABA and ROBERTS, 
1962; FLEXNER et al., 1964). This was attributed to a less effective inhibition of protein 
synthesis than could be obtained following intracerebral injections of puromycin. 
In goldfish, IC injection of 170 pug puromycin results in 80-90 per cent inhibition 
of protein synthesis for 2-8 hr following injection. Behavioural experiments have 
shown that this dose loses half of its effect on memory within 2 hr, while 90 pg of 
puromycin loses all of its effect on memory within the same interval. Both 90 and 
170 p g  of puromycin interfere with memory when injected within 1 hr after trials, but 
50 p g  do not (AGRANOFF et al., 1965). 
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The inhibition seen at 2 hr and 16 hr following the 50 pug injection is similar to 
that seen with 90 pug, although preliminary investigations indicate differences in protein 
inhibition for intervening time points (AGRANOFF et al., 1965). These results could 
mean that some metabolic process involved in memory fixation is secondary to the 
process blocked by protein synthesis and recovers before leucine incorporation returns 
to the normal level. Since we measure total brain protein, the inhibition curve of 
specific proteins involved in the fixation process may be occluded. Protein synthesis 
in a specific locus in the brain which corresponds more closely to the timing of the 
behavioural effect as suggested by FLEXNER et al. (1964) would also be masked in the 
whole brain analyses. If a specific anatomical site is involved, it appears to be rapidly 
accessible to puromycin. 
The proposed mechanism for the depression of protein synthesis by puromycin 
relates the similarity in structure of puromycin to the aminoacyladenosine terminus 
of activated transfer RNA (YARMOLINSKY and DE LA HABA, 1959). Puromycin can 
be attached to the nascent peptide to form peptidyl puromycin which is released from 
the ribosome (MORRIS, FAVELUKES, ARLINGHAUS and SCHWEET, 1962; NATHANS and 
NEIDLE, 1963; NATHANS, 1964). 
To investigate further the possibility that protein synthesis is related to memory 
we sought an inhibitor unrelated in structure to puromycin, and known to be effective 
in vivo in animals. The most potent such agent presently known is AXM (YOUNG, 
ROBINSON and SACKTOR, 1965). A model for its mode of action can be inferred from 
the study of TRAKATELLIS, MONTJAR and AXELROD (1965) who showed that cyclo- 
heximide (a closely related compound) can prevent the transfer of activated amino 
acids to polypeptides and their subsequent release from polysomes. AXM is a 
powerful inhibitor of brain protein synthesis (Table 3 and Fig. 2). AXM also affects 
memory in goldfish (AGRANOFF et al., 1966), although its action on memory disruption 
may not be as marked as that of puromycin. 
It was not possible to inhibit brain protein synthesis by more than 80-90 per cent 
even with relatively large doses of AXM. The residual 10-20 per cent of protein 
synthesis that takes place may reside in areas of the brain that are not readily accessible 
to either drug, or may represent a form of leucine incorporation that is unrelated to the 
effects of these drugs. For example, it was found (CAMPBELL, MAHLER, MOORE and 
TEWARI 1966) that mitochondria1 protein synthesis in rat brain is insensitive to ribo- 
nuclease. 
The effects of actinomycin D are well documented (REICH, FRANKLIN, SHATKIN 
and TATUM, 1962). The major reported effect of this compound is to block DNA- 
dependent formation of RNA. Recent evidence has shown that in various mammalian 
cells it may also (a) accelerate messenger RNA destruction (HARRIS, 1964) (b) block 
protein synthesis directly or by a block which can be abolished by increasing glucose 
levels (HONIG and RABINOVITZ, 1965) and (c) produce a combination of irreversible 
changes which ultimately lead to the death of the animal. Behavioural experiments 
on fish in our laboratory with actinomycin were complicated by decrements in per- 
formance which were independent of the time of injection. Hence a distinction between 
toxic effects unrelated to memory and a specific memory block was not possible. 
Studies on the effects of intracerebrally injected actinomycin D on memory in mice 
by BARONDES and JARVIK (1964) indicated no effect on memory or learning under 
conditions in which brain RNA synthesis was inhibited 80 per cent. 
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S U M M A R Y  
Intraperitoneally injected [3H]leucine is incorporated into goldfish brain protein, 
When puromycin or acetoxycycloheximide is injected intracranially, there is a 
The inhibitory effect of actinomycin D on protein synthesis occurs more slowly, 
the maximum being reached in 4 hr. 
rapid onset of inhibition of incorporation of labelled leucine which lasts for days. 
and becomes maximal a day after injection. 
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